Loading
Washing the abdominal cavity with heated chemotherapy during surgery to kill microscopic peritoneal deposits.
HIPEC exposes the peritoneal cavity directly to chemotherapy heated to 41-43 °C during cytoreductive surgery, achieving high local drug concentration and enhanced penetration into microscopic deposits. A survival benefit was shown in ovarian cancer at interval debulking (OVHIPEC-1) and in pseudomyxoma, but the result was negative in colorectal cancer (PRODIGE 7 for oxaliplatin HIPEC), so the evidence is mixed and indication-specific. PIPAC, pressurised intraperitoneal aerosol chemotherapy, is a palliative laparoscopic alternative for patients who are not candidates for full cytoreduction. Morbidity is substantial and outcomes depend on centre expertise. The simple version is a heated chemotherapy wash of the abdomen during surgery, which helps in some cancers and not others.
Direct peritoneal exposure at 41-43 °C enhances drug penetration.
The chemotherapy given with radiation to cure anal cancer without surgery, used as a bladder instillation after tumour resection, and since 2020-25 in gel form for upper-tract and recurrent bladder cancers.
Complete cytoreductive surgery with modern systemic chemotherapy gives a median survival over 40 months in selected patients with peritoneal metastases, and the heated intraperitoneal oxaliplatin adds only late complications.
The trial that created peritoneal surface malignancy as a speciality, and the reason patients with limited peritoneal disease are referred to designated centres; PRODIGE 7 later showed the benefit belongs to the surgery, not to the heated chemotherapy.
Query for this technology: (TITLE:"hyperthermic intraperitoneal chemotherapy" OR ABSTRACT:"hyperthermic intraperitoneal chemotherapy" OR TITLE:"HIPEC" OR ABSTRACT:"HIPEC" OR TITLE:"PIPAC" OR ABSTRACT:"PIPAC"). Results are unfiltered search hits about HIPEC / PIPAC (intraperitoneal chemotherapy), not a curated reading list.
Shares Intraperitoneal (IP) chemotherapy, HIPEC (hyperthermic intraperitoneal chemotherapy), Debulking (cytoreductive surgery), Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei.
Shares Willemien J. van Driel, OVHIPEC-1, Netherlands Cancer Institute HIPEC trial, Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
Shares Goblet cell adenocarcinoma of the appendix, Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei, Appendiceal cancer and pseudomyxoma peritonei, Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell).
Shares COLOPEC, PROPHYLOCHIP-PRODIGE 15, PRODIGE 7, Colorectal cancer.
Shares Goblet cell adenocarcinoma of the appendix, Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei, Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell).
Shares First Affiliated Hospital of Sun Yat-sen University, Systemic versus local therapy, Mandatory staged registries for new surgical techniques before wide adoption, European Society of Surgical Oncology.
Shares Goblet cell adenocarcinoma of the appendix, Mitomycin C, Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell).
Shares Peritoneal cancer index, Peritoneal metastases from bowel cancer, Goblet cell adenocarcinoma of the appendix, Find peritoneal spread while it is still small, and run complete cytoreduction through networks rather than adding heated chemotherapy.